Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Ovarian|Breast|Prostate|Pancreatic|Advanced Tumours
Interventions: DRUG: olaparib
Sponsor: AstraZeneca